Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase.

AIM The aim of this study was to investigate the biliary secretion of rosuvastatin in healthy volunteers using an intestinal perfusion method after administration of 10mg rosuvastatin dispersion in the intestine. METHODS The Loc-I-Gut tube was positioned in the distal duodenum/proximal jejunum and a semi-open segment was created by inflating the proximal balloon in ten volunteers. A dispersion of 10mg rosuvastatin was administered below the inflated balloon and bile was collected proximally of the inflated balloon. Bile and plasma samples were withdrawn every 20 min during a 4h period (absorption phase) and additional plasma samples were collected 24 and 48 h post-dose. RESULTS The study showed that there is a substantial and immediate transport of rosuvastatin into the human bile, with the maximum concentration appearing 42 min after dosing, 39,000+/-31,000 ng/ml. Approximately 11% of the administered intestinal dose was recovered in the bile after 240 min. At all time points the biliary concentration exceeded the plasma concentration, and the average bile to plasma ratio was 5200+/-9200 (range 89-33,900, median 2000). We were unable to identify any bile-specific metabolites of rosuvastatin in the present study. CONCLUSION Rosuvastatin is excreted via the biliary route in humans, and the transport and accumulation of rosuvastatin in bile compared to that in plasma is rapid and extensive. This intestinal perfusion technique offers a successful way to estimate the biliary secretion for drugs, metabolites and endogenous substances during the absorption phase in healthy volunteers.

[1]  K. Schenck-Gustafsson,et al.  Quinidine reduces biliary clearance of digoxin in man , 1987, European journal of clinical investigation.

[2]  A. Hofmann.  The enterohepatic circulation of bile acids in man. , 1976, Advances in internal medicine.

[3]  P. Tso,et al.  Separation of micelles and vesicles within lumenal aspirates from healthy humans: solubilization of cholesterol after a meal. , 2002, Journal of lipid research.

[4]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[5]  T. Northfield,et al.  Simultaneous quantitative measurements of absolute gallbladder storage and emptying during fasting and eating in humans. , 1987, Gastroenterology.

[6]  R. Subramanian,et al.  Effects of fibrates on metabolism of statins in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[7]  H. Hasegawa,et al.  Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[8]  W. Greco,et al.  Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator , 2005, Clinical Cancer Research.

[9]  A. Hofmann,et al.  Bile sampling, processing and analysis in clinical studies. , 1990, Hepatology.

[10]  Paul D. Martin,et al.  The effect of erythromycin on the pharmacokinetics of rosuvastatin , 2003, European Journal of Clinical Pharmacology.

[11]  D. Meijer,et al.  Pharmacokinetics of biliary excretion in man V , 1983, European Journal of Clinical Pharmacology.

[12]  J. Caldwell,et al.  Biliary excretion of digoxin in man , 1976, Clinical pharmacology and therapeutics.

[13]  A. Dane,et al.  The effect of fluconazole on the pharmacokinetics of rosuvastatin , 2002, European Journal of Clinical Pharmacology.

[14]  B. Angelin,et al.  Ceftriaxone: renal and biliary excretion and effect on the colon microflora. , 1982, The Journal of antimicrobial chemotherapy.

[15]  O. Hernell,et al.  Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. , 1990, Biochemistry.

[16]  W. Heizer,et al.  A novel method for the determination of biliary clearance in humans , 2004, The AAPS Journal.

[17]  T. Sakaeda,et al.  Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  Paul D. Martin,et al.  An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. , 2003, Clinical therapeutics.

[19]  Paul D. Martin,et al.  Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. , 2003, British journal of clinical pharmacology.

[20]  K. Bleasby,et al.  Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C , 2001 .

[21]  D. Meijer,et al.  Pharmacokinetics of biliary excretion in man. VI. Indocyanine green , 2004, European Journal of Clinical Pharmacology.

[22]  E. Shaffer.  Review article: control of gall‐bladder motor function , 2000, Alimentary pharmacology & therapeutics.

[23]  No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG‐CoA Reductase Inhibitor , 2002, Journal of clinical pharmacology.

[24]  H. Lennernäs,et al.  EUFEPS conference on drug transporters at Copenhagen: integrative approaches in ADME research. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  H. Lennernäs,et al.  Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  Paul D. Martin,et al.  Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. , 2003, Clinical therapeutics.

[27]  H. Lennernäs,et al.  Regional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man , 1995, Pharmaceutical Research.

[28]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[29]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[30]  G. Medici,et al.  Determinants of bile secretion: effect of bile salt structure on bile flow and biliary cation secretion. , 1989, Gastroenterology.

[31]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[32]  Paul D. Martin,et al.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin , 2004, Clinical pharmacology and therapeutics.

[33]  U. Gundert-Remy,et al.  Estimation of biliary excretion of ureidopenicillins in healthy volunteers using marker dilution technique. , 1982, British journal of clinical pharmacology.

[34]  Paul D. Martin,et al.  Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. , 2003, Clinical therapeutics.

[35]  K. Lin,et al.  Formulation design of double-layer in the outer shell of dry-coated tablet to modulate lag time and time-controlled dissolution function: Studies on micronized ethylcellulose for dosage form design (VII) , 2004, The AAPS Journal.

[36]  J. Blicklé,et al.  Assessment of biliary excretion of piperacillin-tazobactam in humans , 1997, Antimicrobial agents and chemotherapy.

[37]  H. Lennernäs,et al.  A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[38]  Paul D. Martin,et al.  A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. , 2003, Clinical therapeutics.

[39]  T. Lind,et al.  Biliary secretion of felodipine metabolites in man after intravenous [14C]felodipine , 2006, European Journal of Clinical Pharmacology.

[40]  Michael S. Roberts,et al.  Enterohepatic Circulation , 2002, Clinical pharmacokinetics.

[41]  D. Meijer,et al.  Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. , 1981, British journal of anaesthesia.

[42]  L. Knutson,et al.  A new technique for segmental jejunal perfusion in man. , 1989, The American journal of gastroenterology.

[43]  V. Armstrong,et al.  Acyl Glucuronide Drug Metabolites: Toxicological and Analytical Implications , 2003, Therapeutic drug monitoring.

[44]  D. Meijer,et al.  The Fate of Pancuronium Bromide in Man , 1973, Acta anaesthesiologica Scandinavica.

[45]  Paul D. Martin,et al.  No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers , 2002, Journal of clinical pharmacology.

[46]  G. Kwant,et al.  The excretion of hexafluorenium in man and rat. , 1971, European journal of pharmacology.

[47]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[48]  J. Wierda,et al.  The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. , 1991, European journal of anaesthesiology.

[49]  H. Lennernäs,et al.  A New Approach for Direct In Vivo Dissolution Studies of Poorly Soluble Drugs , 1997, Pharmaceutical Research.